Restoring Bioenergetics in the Traumatized Eye: The Emergence of Mitochondrial Implantation as a Treatment for Acute Ocular Injury
Acute ocular injuries—such as chemical burns, ischemic insults, and mechanical trauma—frequently lead to irreversible vision loss by triggering rapid intracellular adenosine triphosphate (ATP) depletion, mitochondrial calcium overload, severe oxidative stress, and profound mitochondrial dysfunction. Current clinical management primarily focuses on suppressing inflammation and preventing secondary infection, but it fails to address the underlying bioenergetic collapse that drives cellular degeneration. While stem cell and extracellular vesicle therapies have been widely investigated, direct mitochondrial transplantation has recently emerged as a novel strategy for metabolic rescue. This review evaluates the therapeutic potential of exogenously administered mitochondria to mitigate mitochondrial dysfunction and acute trauma in the eye. Emerging preclinical studies demonstrate that transplanted mitochondria can be internalized by selected ocular cell types, conferring short-term cytoprotection, preserving retinal ganglion cell viability, and accelerating corneal epithelial repair. However, robust evidence regarding long-term mitochondrial integration, functional fusion, durable metabolic rescue, and clinical efficacy remains limited. Despite critical challenges in delivery, stability, and dosing, mitochondrial transplantation represents a promising frontier in regenerative ophthalmology that directly targets bioenergetic failure to preserve vision.
To ensure a comprehensive overview of mitochondrial transplantation in acute ocular injury, a structured literature search was conducted across PubMed/MEDLINE, Embase, Web of Science, and Scopus. Literature published up to July 2026 was evaluated, with the final search executed on 1 August 2026.
Searches were conducted using combinations of Medical Subject Headings (MeSH) and free-text terms:
(“Mitochondrial transplantation” OR “mitochondrial transfer” OR “exogenous mitochondria” OR “mitochondrial delivery”) AND (“ocular injury” OR “corneal burn” OR “retinal ischemia” OR “traumatic optic neuropathy” OR “optic nerve crush” OR “cornea” OR “retina”). Broader secondary searches included keywords such as (“Mesenchymal stem cells” OR “Urine-derived stem cells”) AND (“mitochondrial transfer” OR “bioenergetics”).
Inclusion Criteria: (1) Peer-reviewed original research studies (in vitro, in vivo animal models, or clinical reports) investigating therapeutic mitochondrial transfer or transplantation; (2) studies focusing on acute ocular trauma, corneal injury, retinal degeneration, or optic nerve damage; (3) key comparative studies evaluating MSCs, extracellular vesicles, or alternative donor stem cell sources (including USCs).
Exclusion Criteria: Non-English publications, non-peer-reviewed conference abstracts lacking full text, and articles exclusively covering chronic non-ocular metabolic systemic conditions without translational relevance to bioenergetics or organelle transfer.
Selection of Ocular vs. Non-Ocular Studies: Primary emphasis was placed on direct ocular studies (e.g., chemical burns, optic nerve crush, and retinal ischemia–reperfusion). Due to the emerging nature of the ocular field, relevant non-ocular literature (e.g., cardiac or neural mitochondrial transplantation) was selectively included to substantiate foundational mechanisms such as macropinocytosis, TNT formation, EV packaging, and laboratory isolation protocols.
Acute ocular trauma is a leading cause of visual disability worldwide, significantly impacting both civilian and military populations [1]. These injuries, categorized as chemical, thermal, and mechanical trauma, present complex clinical challenges [2,3]. Chemical burns trigger rapid liquefactive necrosis, deep corneal penetration, and the destruction of the limbal stem cell niche [4]. Thermal injuries and mechanical injuries, ranging from penetrating lacerations to blast-induced overpressure, initiate a rapid cascade of tissue disruption and degradation [5]. In the context of modern military operations, blast-related ocular trauma accounts for up to 15% of all battlefield injuries [6]. Despite the diversity of these injuries, they share a common terminal pathway: the rapid onset of irreversible cellular apoptosis and fibrotic scarring, which can result in permanent vision loss [7].
The core of ocular trauma is a metabolic crisis [8]. Retinal and corneal cells are among the most metabolically demanding tissues in the human body. They rely heavily on oxidative phosphorylation to maintain transparency and signal transduction [9]. Following an acute injury, the ocular cellular environment is compromised by ischemia and ionic imbalances [10]. These stressors converge on the mitochondria, leading to the collapse of the mitochondrial membrane potential (ΔΨm) and a subsequent failure in ATP synthesis [10].
This bioenergetic failure triggers a vicious cycle, as the depletion of ATP impairs the function of ion pumps and transporters, including those that maintain intracellular calcium (Ca2+) homeostasis. The resulting mitochondrial Ca2+ overload, together with oxidative stress, triggers opening of the mitochondrial permeability transition pore (mPTP), a mechanism discussed in detail in Section 1.3 [11]. Consequently, mitochondria release pro-apoptotic factors, such as cytochrome c, into the cytoplasm, whilst generating a burst of ROS [12]. This shifts the cellular state from survival to programmed cell death (Figure 1), suggesting that mitochondrial dysfunction is not a byproduct of trauma, but the primary driver of irreversible damage.
Current clinical protocols for acute ocular injury are primarily reactive rather than restorative. The leading standard of care focuses on suppressing inflammation through corticosteroids and preventing infection via prophylactic antibiotics [13]. While effective, these interventions do not address the underlying bioenergetic deficit the ocular cells undergo [14]. Corticosteroids, particularly, may offer symptomatic relief but can also delay epithelial healing, induce cataract, and increase intraocular pressure [15]. Furthermore, advanced surgical interventions, such as corneal transplantation or retinal surgery, are often deferred until the chronic stage of injury, by which time the regenerative capacity of the endogenous tissue is incapacitated or terminated [16]. There is currently no approved therapeutic modality that targets the immediate metabolic failure of the damaged cells. This therapeutic gap highlights the urgent need for “bioenergetic resuscitation”, a novel strategy that directly restores cellular energy production to prevent the transition from acute injury to permanent blindness.
Among the ionic disturbances that follow acute ocular injury, dysregulation of Ca2+ homeostasis deserves particular emphasis because it links the initial insult directly to mitochondrial failure and cell death. Under physiological conditions, mitochondria are, together with the endoplasmic reticulum (ER), one of the principal intracellular Ca2+ stores. Driven by the strongly negative ΔΨm, Ca2+ enters the mitochondrial matrix through the mitochondrial calcium uniporter (MCU) complex and is extruded mainly by Na+/Ca2+ exchange. This allows mitochondria to shape cytosolic Ca2+ transients and to couple Ca2+ signals to the activity of matrix dehydrogenases and ATP production [17].
Acute injury disturbs this balance from two directions. First, Ca2+ enters from the extracellular space. ATP depletion compromises the plasma membrane Ca2+-ATPase and the Na+/K+-ATPase, and the resulting membrane depolarization, intracellular Na+ accumulation, and reversal of Na+/Ca2+ exchange favour Ca2+ entry [10]. In the retina, ischemia additionally causes excessive release of glutamate, which activates N-methyl-D-aspartate (NMDA) receptors and voltage-gated Ca2+ channels and produces a large Ca2+ influx into inner retinal neurons [18]. Second, Ca2+ is released from the ER: impaired activity of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) and Ca2+ efflux through inositol 1,4,5-trisphosphate and ryanodine receptors deplete ER stores. Because the ER is physically tethered to mitochondria at mitochondria-associated membranes, a substantial fraction of this Ca2+ is delivered directly to the mitochondrial surface [17]. Mitochondria initially buffer the rising cytosolic Ca2+, but this protective uptake becomes harmful once their capacity is exceeded [11,17].
Matrix Ca2+ overload, particularly in combination with oxidative stress, inorganic phosphate, and depletion of adenine nucleotides, triggers opening of the mPTP, a high-conductance, non-selective channel in the inner mitochondrial membrane [11,19]. Sustained mPTP opening collapses ΔΨm and uncouples oxidative phosphorylation, so that the ATP synthase may hydrolyse rather than produce ATP. It also causes large-amplitude swelling of the matrix, rupture of the outer mitochondrial membrane, and release of cytochrome c and other intermembrane-space proteins into the cytosol [11,19]. Released cytochrome c then activates the caspase cascade and apoptosis [12]. When ATP depletion is severe, the same mPTP-driven bioenergetic collapse leads instead to necrotic cell death, so that the extent of the permeability transition largely determines both whether and how injured cells die [11]. Moreover, because ΔΨm is the driving force for mitochondrial Ca2+ uptake, depolarized mitochondria lose their capacity to buffer Ca2+, which further amplifies cytosolic Ca2+ overload and perpetuates the vicious cycle described above [11,17].
This sequence is of particular importance in ophthalmology because retinal and optic nerve cells are highly Ca2+-sensitive. Retinal ganglion cells (RGCs) are especially vulnerable to excitotoxic Ca2+ influx during retinal ischemia, and in experimental models, agents that block NMDA receptors or voltage-gated Ca2+ channels reduce ischemic retinal damage [18]. In the optic nerve, in vivo imaging after crush injury has shown a rapid rise in intra-axonal Ca2+; Ca2+ channel blockers attenuated both this rise and the subsequent acute axonal degeneration, whereas a Ca2+ ionophore aggravated it [20]. In glaucomatous optic neuropathy, which shares several downstream mechanisms with traumatic optic neuropathy, Ca2+-dependent intracellular cascades have likewise been implicated in progressive RGC and axonal degeneration [21]. Comparable data for corneal cells after chemical injury are more limited, and the contribution of mitochondrial Ca2+ overload to corneal damage remains to be defined. Mitochondrial Ca2+ overload and mPTP opening therefore represent a point of convergence at which the ionic disturbances of ischemic and mechanical ocular injury are converted into irreversible bioenergetic failure [11,19]. Accordingly, an effective bioenergetic rescue strategy should aim not only to restore ATP production but also to re-establish mitochondrial Ca2+ buffering capacity. The potential of mitochondrial transplantation in this regard is discussed in Section 4.3.
The transfer of exogenous mitochondria into recipient cells is no longer seen as a passive occurrence but as a highly regulated biological process. In acute ocular injury, the goal is for damaged host cells to rapidly “uptake” healthy mitochondria to stop the apoptotic cascade. There are several mechanisms by which mitochondria can be internalized by recipient cells.
Macropinocytosis: Macropinocytosis is a form of endocytosis where the cell membrane folds inward to create large vesicles that engulf extracellular fluids and particles. This is the most documented pathway for “naked” mitochondrial uptake. Research suggests that when healthy mitochondria are injected, usually intravitreally, they trigger the activation of the actin cytoskeleton in damaged retinal cells, leading to their engulfment [22]. Molecules like PI3K and Rac1 are essential for this membrane remodeling.
Tunneling Nanotubes (TNTs): TNTs are long, thin, actin-based bridges that connect two or more cells over long distances. In a therapeutic setting, if MSCs are used as a delivery vehicle, these cells can extend TNTs directly into the injured ocular cells [23]. This is often more efficient than injecting isolated mitochondria because the mitochondria are pushed through the tube, protecting them from the extracellular environment.
Gap Junctions and Microvesicles: These are protein channels (e.g., connexins) that allow for the passage of smaller mitochondrial components or signals that prime the host cell for better metabolic function [24]. Often, mitochondria are packaged into microvesicles by the donor cell. These vesicles then fuse with the plasma membrane of the injured eye tissue, releasing the mitochondria directly into the cytoplasm.
The Role of the “Danger Signal”: Internalization is significantly enhanced in injured cells compared to healthy ones [25]. Acute ocular trauma releases signals (like Ca2+ spikes or specific chemokines) that act as a “find me” or “eat me” signal for the therapeutic mitochondria [26]. These extracellular Ca2+ signals, which may facilitate organelle uptake, should be distinguished from the intracellular mitochondrial Ca2+ overload that drives cell death (Section 1.3). This inherent targeting makes mitochondrial therapy particularly effective for localized trauma like corneal burns or optic nerve crush.
Overall, the success of mitochondrial transplantation in the ocular environment hinges on the efficiency of internalization pathways. Unlike smaller molecules, the 0.5–1.0 µm size of the mitochondrion requires active transport mechanisms [27]. Macropinocytosis remains the predominant pathway for isolated mitochondrial uptake, governed by actin polymerization and GTPase activity [28]. However, in cellular-based therapies, such as the application of stem cells to the ocular surface, the formation of TNTs provides a direct conduit for organelle transfer. Understanding these pathways is essential for optimizing delivery dosages and ensuring the metabolic rescue of the retinal and corneal bioenergetic landscapes.
Multiple mechanisms have been proposed to explain the transfer of exogenous mitochondria into recipient cells, including macropinocytosis, endocytosis, membrane fusion, extracellular vesicle-mediated transport, and tunneling nanotubes (TNTs). While numerous studies have reported intracellular localization of donor mitochondrial signals following transplantation, the interpretation of these findings requires caution because the intracellular fate of transplanted mitochondria remains incompletely understood.
Fluorescent Detection Does Not Necessarily Demonstrate Functional Mitochondrial Transfer: Many studies rely on fluorescent dyes, mitochondrial-targeted fluorescent proteins, or quantum-dot labeling to track donor mitochondria [29,30]. However, detection of fluorescent signals within recipient cells does not necessarily demonstrate that intact, functional mitochondria have been successfully transplanted [31]. Fluorescent labels may persist following mitochondrial fragmentation, membrane disruption, or degradation and may potentially transfer independently of intact organelles.
Intact Organelle Uptake Versus Mitochondrial Fragments: An important unresolved question is whether recipient cells internalize complete mitochondria or merely mitochondrial fragments and associated biomolecules. Most current imaging approaches lack sufficient spatial resolution to distinguish between these possibilities.
Endocytic Uptake and Lysosomal Degradation: Macropinocytosis is frequently proposed as a major mechanism of mitochondrial internalization. However, uptake via endocytic pathways raises the possibility that transplanted mitochondria may subsequently traffic to lysosomes and undergo degradation rather than contribute to host–cell metabolism.
Mitochondrial Fusion, Fission, and Network Incorporation: Functional incorporation into host cells likely requires participation in normal fusion-fission dynamics regulated by proteins such as MFN1, MFN2, OPA1, and DRP1. Evidence demonstrating direct fusion between donor and host mitochondria remains limited in ocular systems.
Donor mtDNA Persistence, Heteroplasmy, and Mitophagy: Few ocular studies have examined mtDNA durability, heteroplasmy, or mitophagic clearance of transplanted mitochondria after uptake.
Defining Functional Integration: For the purposes of this review, functional integration is defined as meeting several criteria: (1) intracellular uptake of intact donor mitochondria; (2) evasion of lysosomal degradation; (3) participation in host mitochondrial network dynamics; (4) restoration or enhancement of oxidative phosphorylation, ATP production, or mitochondrial membrane potential; (5) persistence of donor mitochondrial function beyond transient intracellular detection; and (6) evidence of therapeutic benefit attributable to donor mitochondrial activity rather than indirect signaling effects.
The efficacy of mitochondrial transplantation in the eye is largely dependent on the quality of the donor source and the precision of the delivery route. While various cell types have been explored, mesenchymal stem cells (MSCs) are emerging as a superior candidate for organelle donation.
MSCs as a Potent Mitochondrial Donor: MSCs are a promising source for mitochondrial transplantation due to their accessibility, biological resilience, and capacity for intercellular organelle transfer. Traditionally, they are derived from bone marrow, adipose tissue, and perinatal tissues [32]. However, MSC-like populations can be isolated from non-invasive sources such as urine, increasing accessibility [33]. This circumvents the need for procedures like bone marrow aspiration, enabling repeated sampling and the potential establishment of patient-specific “mitochondrial banks” [34]. It also reduces immunogenic risks and allows for personalization of therapeutic strategies [35]. For acute ocular injury rapid intervention is critical [36]. The accessibility of MSCs facilitates the timely delivery of therapeutic mitochondria.